CN107922609B - 基于阳离子粘酸聚合物的递送系统 - Google Patents

基于阳离子粘酸聚合物的递送系统 Download PDF

Info

Publication number
CN107922609B
CN107922609B CN201680050424.6A CN201680050424A CN107922609B CN 107922609 B CN107922609 B CN 107922609B CN 201680050424 A CN201680050424 A CN 201680050424A CN 107922609 B CN107922609 B CN 107922609B
Authority
CN
China
Prior art keywords
polymer
cmap
nanoparticle
independently
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680050424.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922609A (zh
Inventor
马克·E·戴维斯
多罗西·潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Priority to CN202010303591.5A priority Critical patent/CN111643479B/zh
Publication of CN107922609A publication Critical patent/CN107922609A/zh
Application granted granted Critical
Publication of CN107922609B publication Critical patent/CN107922609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/08—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing boron
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CN201680050424.6A 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统 Active CN107922609B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010303591.5A CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187366P 2015-07-01 2015-07-01
US62/187,366 2015-07-01
PCT/US2016/037166 WO2017003668A1 (en) 2015-07-01 2016-06-13 Cationic mucic acid polymer-based delivery systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010303591.5A Division CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Publications (2)

Publication Number Publication Date
CN107922609A CN107922609A (zh) 2018-04-17
CN107922609B true CN107922609B (zh) 2020-04-24

Family

ID=57609004

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680050424.6A Active CN107922609B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统
CN202010303591.5A Active CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010303591.5A Active CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Country Status (6)

Country Link
US (4) US10287401B2 (https=)
EP (2) EP3795609B1 (https=)
JP (4) JP6914860B2 (https=)
CN (2) CN107922609B (https=)
ES (2) ES2980216T3 (https=)
WO (1) WO2017003668A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
CN113905786A (zh) * 2019-05-29 2022-01-07 国立大学法人东京工业大学 复合物、药物、癌症治疗剂、试剂盒和缀合物
CN115298189B (zh) 2019-12-04 2024-08-30 丹塔里股份有限公司 合成治疗性纳米颗粒的方法和组合物
JP7343874B2 (ja) * 2019-12-26 2023-09-13 株式会社島津製作所 データ処理方法及びデータ処理装置
AU2024246833A1 (en) 2023-03-31 2025-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6034081A (en) 1995-05-30 2000-03-07 Buckman Laboratories International Inc Potentiation of biocide activity using an N-alkyl heterocyclic compound
US5693631A (en) 1995-05-30 1997-12-02 Buckman Laboratories International, Inc. Potentiation of the microbicide 2-(thiocyanomethylthio) benzothiazole using an N-alkyl heterocyclic compound
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5596878A (en) 1995-06-26 1997-01-28 Thermo King Corporation Methods and apparatus for operating a refrigeration unit
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
FR2749853B1 (fr) 1996-06-12 1998-10-16 Rhone Poulenc Chimie Formulation amelioree a base d'un compose hydroxyle et d'un compose amphiphile complexant utilisable notamment pour modifier les proprietes rheologiques d'emulsions
EP0920339A2 (en) 1996-07-09 1999-06-09 The Johns Hopkins University Gene delivery system
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
ES2210808T3 (es) 1997-08-27 2004-07-01 California Institute Of Technology Composiciones y su uso para prevenir la formacion de adherencias en un tejido biologico.
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
WO2000010007A2 (en) 1998-08-17 2000-02-24 California Institute Of Technology Devices and methods for analysis of non-ionic solutes
US6350527B1 (en) 1998-08-27 2002-02-26 Eidgenossische Technische Hochschule Zurich Gels and multilayer surface structures from boronic acid containing polymers
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
HRP20021005A2 (en) 2000-06-22 2004-02-29 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
PL204958B1 (pl) 2000-06-30 2010-02-26 Glaxo Group Ltd Ditosylany związków chinazolinowych, środek farmaceutyczny i zastosowanie tych związków
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
ES2304467T3 (es) 2001-07-10 2008-10-16 North Carolina State University Vehiculo de liberacion de nanoparticulas.
EP1416799A4 (en) 2001-07-23 2004-11-10 Univ Ramot METHOD AND COMPOSITIONS FOR TREATING MUSHROOM INFECTIONS
US6737504B2 (en) 2001-07-30 2004-05-18 California Institute Of Technology Synthesis of substituted poly(aniline)s
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
US6984653B2 (en) 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
PL373848A1 (en) 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
GEP20063872B (en) 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
EP1463507A1 (en) 2001-12-19 2004-10-06 SmithKline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1510221A4 (en) 2002-06-03 2009-04-29 Mitsubishi Tanabe Pharma Corp MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
AU2003291567A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
US7923032B2 (en) 2002-11-26 2011-04-12 Seacoast Neuroscience, Inc. Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
JP2005119255A (ja) 2003-10-17 2005-05-12 San Quest:Kk 携帯電話画像取り込み機能付き名刺印刷装置
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US7399645B2 (en) 2004-05-12 2008-07-15 Applera Corporation Constrained cis-diol-borate bioconjugation system
EP1773900A4 (en) 2004-07-30 2007-08-29 Basf Ag POLYMERIC BORONIC ACID DERIVATIVES AND USE IN THE MANUFACTURE OF PAPER
US7413173B2 (en) 2004-09-10 2008-08-19 Ric Investments, Llc Molded water chamber base plate for use in a humidifier and ventilator assembly
US7867774B2 (en) 2004-10-12 2011-01-11 Luminex Corporation Methods for altering surface characteristics of microspheres
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
AU2006293410B2 (en) 2005-09-20 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoparticles for targeted delivery of active agents
US7988988B2 (en) 2005-11-21 2011-08-02 Bausch & Lomb Incorporated Contact lenses with mucin affinity
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
EP2054043A2 (en) 2006-08-17 2009-05-06 Novartis AG Nanoparticle compositions
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2009036022A1 (en) 2007-09-10 2009-03-19 Board Of Regents, The University Of Texas System Enhancement of polysaccharide-mediated nucleic acid delivery
US8377474B2 (en) 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
US20100029545A1 (en) 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
US8367166B2 (en) 2008-10-31 2013-02-05 Chevron U.S.A. Inc. Synthesis of higher diamondoids
US20120156138A1 (en) 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
FR2946476B1 (fr) 2009-06-05 2014-03-21 Aeg Power Solutions Bv Convertisseur continu-continu a regulation double alternance
US20100330686A1 (en) 2009-06-29 2010-12-30 Seung Bum Park Nanosensor for sugar detection
WO2011057225A2 (en) 2009-11-06 2011-05-12 University Of Washington Through Its Center For Commercialization Self-assembled particles from zwitterionic polymers and related methods
US9138418B2 (en) 2009-12-09 2015-09-22 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
US20120309691A1 (en) 2010-02-04 2012-12-06 Dapeng Zhou Tumor targeted delivery of immunomodulators by nanopolymers
US20130157926A1 (en) 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
EA201390145A1 (ru) 2010-08-20 2013-11-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции и связанные с ними способы
US20120148489A1 (en) 2010-12-10 2012-06-14 California Institute Of Technology Targeting Kidney Mesangium With Nanoparticles of Defined Diameter
EP2707419B1 (en) 2011-05-13 2019-08-14 The Regents of The University of California Reversibly crosslinked micelle systems
DE102012017025B4 (de) 2012-08-28 2018-05-30 Kennametal Inc. Werkzeughalter für einen Schneideinsatz und Baugruppe mit einem solchen Werkzeughalter
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
ES2737800T3 (es) * 2013-03-01 2020-01-16 California Inst Of Techn Nanopartículas estabilizadas con composiciones de ácido nitrofenilborónico
US9468681B2 (en) * 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
ES2986545T3 (es) 2013-03-01 2024-11-11 California Inst Of Techn Nanopartículas dirigidas
US20140348754A1 (en) 2013-05-14 2014-11-27 California Institute Of Technology Method of Delivering Therapeutics and Imaging Agents to the Brain by Nanoparticles that Cross the Blood Brain Barrier
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム

Also Published As

Publication number Publication date
JP2025100542A (ja) 2025-07-03
ES2980216T3 (es) 2024-09-30
US10717825B2 (en) 2020-07-21
EP3317323A1 (en) 2018-05-09
JP6914860B2 (ja) 2021-08-04
JP2018525462A (ja) 2018-09-06
ES2882255T3 (es) 2021-12-01
JP2021181568A (ja) 2021-11-25
CN111643479B (zh) 2023-10-27
US20170002151A1 (en) 2017-01-05
JP7150945B2 (ja) 2022-10-11
JP7708728B2 (ja) 2025-07-15
US11041050B2 (en) 2021-06-22
EP3795609A1 (en) 2021-03-24
JP2022191285A (ja) 2022-12-27
EP3317323A4 (en) 2019-05-29
CN107922609A (zh) 2018-04-17
US20200283582A1 (en) 2020-09-10
CN111643479A (zh) 2020-09-11
US10287401B2 (en) 2019-05-14
EP3795609B1 (en) 2024-04-03
US20190202995A1 (en) 2019-07-04
US20210261739A1 (en) 2021-08-26
WO2017003668A1 (en) 2017-01-05
EP3317323B1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
CN107922609B (zh) 基于阳离子粘酸聚合物的递送系统
Chang et al. Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery
KR101444274B1 (ko) 약제복합체용 블록 공중합체 및 의약조성물
JP7046321B2 (ja) 修飾されたスチレン－無水マレイン酸共重合体及びその使用
CN113754793B (zh) 一种苯硼酸枝接的壳寡糖衍生物及其制备方法和应用
AU2007350282A1 (en) Dendrimers and methods of making and using thereof
Nie et al. In vitro and in vivo evaluation of stimuli-responsive vesicle from PEGylated hyperbranched PAMAM-doxorubicin conjugate for gastric cancer therapy
CN101180319B (zh) 醛结合的类黄酮制剂
CN102526756A (zh) 阿霉素复合物、胶束及胶束的制备方法
CN110755633B (zh) 一种双pH敏感负载化疗药物柔红霉素的纳米传递系统的制备方法
CN111743861B (zh) 靶向三阴性乳腺癌的低氧响应手性药物胶束及其制备方法
WO2011065916A1 (en) Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel
Zhao et al. Self-assembled thermosensitive nanoparticles based on oligoethylene glycol dendron conjugated doxorubicin: preparation, and efficient delivery of free doxorubicin
JP7739406B2 (ja) 含ハロゲン部位を有するポリマーおよび該ポリマーを用いた医薬組成物
CN114573729A (zh) 一种线粒体靶向的糖原衍生物药物载体及其在药物递送领域的应用
CN112961338A (zh) 一种pH敏感的普朗尼克交联剂、制备方法与应用
CN115957344B (zh) 一种共靶向肿瘤细胞和m2型巨噬细胞的载体和纳米递药系统及其制备方法
KR20120120712A (ko) 헤파린-도세탁셀-토로콜산 접합체로 이루어진 표적성이 향상된 수용성 항암제 및 그의 제조방법
CN102716088A (zh) 叶酸偶联壳聚糖川芎嗪纳米粒制剂
CN120053673A (zh) 纳米前药及其制备方法和用途
CN121943880A (zh) 一种抗肿瘤小分子组合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant